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Context: The two main subtypes of pseudohypoparathyroidism (PHP), PHP-Ia and -Ib, are caused
by mutations in GNAS exons 1-13 and methylation defects in the imprinted GNAS cluster, respec-
tively. PHP-Ia patients showAlbright hereditary osteodystrophy (AHO) and resistance toward PTH
and additional hormones, whereas PHP-Ib patients do not have AHO, and hormone resistance
appears to be limited to PTH and TSH. Recently, methylation defects have been detected in few
patients with PHP and mild AHO, indicating a molecular overlap between the two forms.
Objectives: The aim of the study was to screen patients with clinically diagnosed PHP-Ia for meth-
ylationdefects and to investigate thepresenceof correlations between themolecular findings and
AHO severity.
Patients and Methods: We investigated differential methylation of GNAS regions and STX16
microdeletions ingenomicDNA from40patientswith sporadicAHOandmultihormone resistance,
with no mutations in Gs-coding GNAS exons.
Results:Molecular analysis showed GNAS cluster imprinting defects in 24 of the 40 patients ana-
lyzed.No STX16deletionwasdetected. Thepresenceof imprintingdefectswasnot associatedwith
the severity of AHO or with specific AHO signs.
Conclusions:We report the largest series of the literature of patients with clinical AHO andmulti-
hormone resistance and no mutation in the Gs gene. Our findings of frequent GNAS imprinting
defects further confirm the existence of an overlap between molecular and clinical features of
PHP-Ia and PHP-Ib and highlight the necessity of a new clinical classification of the disease that
takes into account the recent knowledge on the molecular basis underlying these defects. (J Clin
Endocrinol Metab 95: 0000–0000, 2010)
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Pseudohypoparathyroidism (PHP) refers to a heteroge-neous group of rare metabolic disorders character-
izedby resistance to theactionofPTH(1,2).The twomain
subtypes of PHP, PHP type Ia and Ib (PHP-Ia, PHP-Ib) are
caused bymolecular alterations within or upstream of the
GNAS locus. In particular, heterozygous loss of function
mutations in exons 1-13 of the gene encoding Gs (the
-subunit of heterotrimeric stimulatory G protein) inher-
ited from the mother lead to PHP-Ia, in which Albright
hereditary osteodystrophy (AHO), a disorder character-
ized by a constellation of physical features [short stature,
rounded face, brachydactyly, ectopic ossifications, and
various degrees ofmental retardation (MR)], is associated
with end-organ resistance to the action of different hor-
mones that activate the Gs-coupled pathways, primarily
PTH, TSH, gonadotropins (reviewed in Refs. 1, 3, and 4)
and, more recently reported, GHRH (5, 6). The samemu-
tations inherited from the father lead to pseudo-PHP, in
which AHO occurs in the absence of endocrine abnor-
malities. Most patients with PHP-Ia show a partial defi-
ciency (50%) of Gs activity in red blood cells (7), due to a
reduction in its -subunit mRNA and protein. Although
GNASmutations are identified in the majority of patients
with PHP-Ia and in their relatives affected with pseudo-
PHP, in about 30% patients the molecular diagnosis re-
mains to be ascertained (1).
Besides Gs, GNAS gives rise to several other tran-
scripts, including XLs, A/B (also referred to as 1A),
NESP55, and AS. The complexity of the GNAS locus is
further reflected by a parent-specific methylation pattern
of most of its different promoters (Fig. 1A) (reviewed in
Ref. 8). In PHP-Ib patients, AHO is absent, Gs activity in
erythrocytes and fibroblast is normal, and hormone resis-
tance is limited to PTH and TSH, the latter being essen-
tially always subclinical (9, 10). This disorder is caused by
the disruption of long-range imprinting control elements
inGNAS locus. In particular, the most consistent defect is
the loss of imprinting at the exon A/B differentially meth-
ylated region (DMR), with consequent presumed de-
creased Gs transcription in tissues where this protein is
derived from thematernal allele only. The familial formof
the disease (AD-PHP-Ib) is typically associated with an
isolated loss of imprinting at the exonA/BDMR, together
with microdeletions disrupting the upstream STX16 gene
as the cause of the epigenetic disruption (11, 12). In ad-
dition, deletions removing the entire NESP55 DMR have
been identified in some AD-PHP-Ib kindreds in whom af-
fected individuals show loss of all the maternal GNAS
imprints (13). Conversely, most sporadic PHP-Ib cases
have GNAS imprinting abnormalities that involve multi-
ple DMRs, but the genetic lesion, if any, underlying these
defects remains to be discovered (reviewed in Refs. 14 and
15). Interestingly, in both PHP-Ia and familial PHP-Ib,
hormonal resistance develops only after maternal inheri-
tance of the mutation/deletion, consistent with the recent
finding of tissue-specific paternal imprinting of the Gs
gene in those tissues resistant to hormone action in the two
diseases (16–18).
Recently, three independent studies reportedmethylation
defects similar to thoseobserved inPHP-Ib in a total of seven
patients clinically diagnosed with PHP-Ia, six of whom dis-
played mild features of AHO (19–21). In the present study,
we analyzed the presence of GNAS imprinting defects in a
large series of patients with a likely clinical diagnosis of
PHP-Ia and absence of mutations in Gs-coding exons, in
whom AHO features varied from mild to severe, and we
foundthatmore thanhalfof thesepatients couldbeclassified
at the molecular level as sporadic PHP-Ib.
Patients and Methods
Sequencing analysis of the GNAS gene
GenomicDNAwas extracted fromperipheral blood leukocytes
(Nucleon BACC kit; GE Healthcare, Little Chalfont, UK). The
Gs-coding GNAS exons (exons 1-13) were then amplified by
PCRusing the specific primer pairs and conditions previously pub-
lished (22). Amplification of all exons included each bordering
intron region; the following new primer pair for exon 1 was used:
SE, 5-CCTCCCGGCCCGCGTGA-3; and AS, 5-CTGC-
GGGGCGCCCTTCGA-3. Direct sequencing of the amplified
fragments was then performed using the BigDye Terminator v3.1
Cycle Sequencing Kit and 310 Genetic Analyzer (Applied Biosys-
tems, Foster City, CA).
Moreover, to rule out deletions in the upstream region of
GNAS, we performed genotyping byPCRanddirect sequencing of
a known polymorphic pentanucleotide repeat within the A/B
DMR (19, 23), at six polymorphic sites within the NESP55 region
(rs 1800900, rs 1800901, rs 1800902, rs 1800903, rs 1800904,
and rs 1800905) and eight polymorphic sites within the XL-A/B
intronic region (rs 35113254, rs 2145288, rs 6026567, rs
12625436, rs 7271854, rs 6123836, rs 6026574, and rs 4812042)
(24). The primer pairs and conditions used for the specific ampli-
fication of these regions are available on request.
Methylation analysis of GNAS
Differential methylation of GNAS DMRs A/B, AS, XL, and
NESP was assessed on bisulfite-treated DNA using highly quan-
titative analysis based on PCR-pyrosequencing, as previously
reported (25). In brief, 1 g DNA (concentration 50 ng/l) was
treated using the EZ DNA Methylation-Gold Kit (Zymo Re-
search, Orange, CA) according to the manufacturer’s protocol,
andPCRwas amplified. PCRprimers for the amplificationof the
four differentGNAS exonswere specifically designed to amplify
themodifiedDNA (10). For each reaction, a PCRwas conducted
in 50 l of Platinum Taq DNA Polymerase High Fidelity (In-
vitrogen S.R.L., Milano, Italy), 1 pmol of the forward primer, 1
pmol of the reverse primer, 50 ng of bisulfite-treated genomic
DNA, and water. Primer sequences are reported in Supplemen-
tary Table 1 (published as supplemental data on The Endocrine
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Society’s Journals Online web site at http://jcem.endojournals.
org). One of the forward or reverse primers was biotin-labeled,
depending on the proximity toCG sites to be quantified andused
to purify the final PCR product using Sepharose beads. The PCR
product was bound to Streptavidin Sepharose HP (Amersham
Biosciences, Uppsala, Sweden), and the Sepharose beads con-
taining the immobilized PCR product were purified, washed,
denaturedusing a0.2MNaOHsolution, andwashed again using
the Pyrosequencing Vacuum Prep Tool (Pyrosequencing, West-
borough,MA), as recommended by the manufacturer. A 0.3 M
FIG. 1. A, General organization and imprinting of GNAS. The maternal and paternal alleles of GNAS are shown, and arrows indicate the direction
of transcription. The alternative first exons and common exons 2-13 are shown as rectangles: white for the paternally derived ones, gray for the
maternally derived NESP55, and striped for the biallelically transcribed exon 1, i.e. the first coding exon for Gs. Vertical lines indicate the position
of the SNPs analyzed: in the NESP region, the SNP location partially overlaps with the DMR studied. The diagram is not drawn to scale. B, STX16
gene 3-kb (left) and 4.4-kb (right) deletions analysis. Exons are depicted as black boxes, and direct repeats are shown as arrowheads. The 3-kb
deleted region lies between the direct repeats and causes the loss of STX16 exons 4-6. Amplification of the STX16 region with four different
primers, located at nucleotides 3606 [primer A (forward)], 4572 [primer C (reverse)], 6455 [primer D (forward)], and 7951 [primer B (reverse)] of
AL139349 is shown. When performing multiplex PCR, all these primers are included in the reaction. The amplicons obtained are shown as black
lines. The expected sizes of wild-type PCR products are 4.5 Kb (primers A and B), 1496 bp (primers D and B), and 966 bp (primers A and C).
Obligate carriers and affected individuals show an additional 1387 bp amplicon (primers A and B) that is amplified on the deleted allele (data not
shown). The right panel shows the 4.4-kb deleted region that lies between exons 1-4. Amplification of this STX16 region with four different
primers at 404, 1020, 4902, and 5193 of AL139349 [primer A1 (forward); primer C1 (reverse); primer D1 (forward); and primer B1 (reverse),
respectively] is shown. The expected sizes of wild-type PCR products are 4.8 Kb (primers A1 and B1), 616 bp (primers A1 and C1), and 291 bp
(primers D1 and B1). Affected individuals show an additional 417-bp amplicon. C, Methylation analysis of GNAS DMRs in patient 3 (PT; as a
representative sample) and a normal control (WT). Genomic DNA from each subject included in the study was bisulfite treated, and each GNAS
DMR was amplified using specific primers. Representative pyrograms for each analyzed locus are shown the figure. The x-axis represents the DMR
sequence, whereas the y-axis shows the percentage of incorporated nucleotide for each given position. The upper panel shows the normal CpG
pattern of methylation in a wild-type subject, whereas the lower panel demonstrates methylation alterations (indicated by arrows) at the same
position in a representative patient. D, STX16 deletion analysis performed by multiplex PCR. Long-range PCR analysis is performed using only
primers A and B or A1 and B1 (data not shown). When multiplex PCR is used for the identification of the deletions (4.4 kb, upper panel; 3 kb,
lower panel), normal subjects show two PCR products (1496 bp and 966 bp for 3-kb deletion; 616 bp and 291 bp for 4.4-kb deletion), whereas
deleted patients show an additional band of 1387 bp and 417 bp, respectively. Here, we show the results obtained for a normal control (C), a
known patient bearing the 3-kb deletion (C), and a group of five representative samples: patients 25 (P25) and 26 (P26), with normal
methylation pattern; patients 3 (P3), 6 (P6), and 23 (P23) with altered methylation pattern.
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pyrosequencing primer was then annealed to the purified single-
stranded PCR product, and pyrosequencing was performed us-
ing the PyroMark MD (Pyrosequencing). Methylation quantifi-
cationwasperformedusing the provided software. Thedegree of
methylation was expressed for each considered DNA locus as
percentage of methylated cytosines divided by the sum of meth-
ylated and unmethylated cytosines. We used built-in controls to
verify bisulfite conversion efficiency. Every sample was tested
three times for eachmarker to confirm the reproducibility of our
results, and the mean obtained is shown in Table 1.
Detection of the 3-kb and 4.4-kb deletions in
STX16
We investigated the presence of STX16 deletions on patients’
genomic DNA by both long-range and multiplex PCR tech-
TABLE 1. Clinical characteristics and molecular analysis of patients included in the present study
Pt Sex
Age
1
Age
2
PTH
(pg/ml)
TSH
(mIU/liter)
Height
(SDS) AHO features
Abnormal
methylation
Methylation %
AB NESP AS XL
1 F 9 12 795 6.2 148 (0.2) Br/RF AB/NESP/AS/XL 9 87 5 12
2 M 22 8 380 7.1 113 (3.1) Br/SS/RF/Ob/SO/MR AB/NESP/AS/XL 11 81 13 15
3 F 22 6 256 4.8 99 (2.5) Br/SS/RF/Ob/SO/MR AB/NESP/AS/XL 5 95 8 7
4 F 18 8 401 12.3 111 (2.6) Br/SS/RF/Ob/SO/MR AB/NESP/AS/XL 3 88 13 6
5 F 15 12 83 4.5 138 (1.8) Br/SS/RF/Ob/SO/MR AB/NESP/AS/XL 12 90 9 10
6 F 4 8 391 6.6 112 (2.0) SS/RF/Ob/SO/MR AB/NESP/AS/XL 8 86 12 18
7 M 3 4 90 20.5 92 (2.2) Br*/SS/RF/MR AB/NESP/AS/XL 3 93 7 9
8 M 3 7 95 4.8 107 (2.7) Br/SS/RF/Ob/MR AB/NESP/AS/XL 10 97 15 13
9 M 8 10 227 14 140 (0.7) Br/RF/Ob/SO/MR AB/NESP/AS/XL 12 85 11 11
10 M 3 12 203 5.6 130 (3.2) SS/RF AB/NESP/AS/XL 12 90 9 19
11 F 5 13 75 5.3 139 (3.0) Br/SS/RF AB/NESP/AS/XL 4 96 6 7
12 F 2 10 312 16.2 122 (2.5) Br/SS AB/NESP/AS/XL 5 89 8 9
13 F 8 12 260 25.6 157 (0.5) Br*/RF/Ob AB/NESP/AS/XL 12 90 9 5
14 F 4 18 188 5.2 163 (0.1) Br/RF/Ob AB/NESP/AS/XL 7 93 8 8
15 M 2 9 216 14.2 170 (1.0) Br/RF AB/NESP/AS/XL 10 84 15 10
16 M 13 13 256 5.0 137 (2.2) Br/SS/RF/Ob/SO AB/NESP/AS/XL 7 97 8 8
17 Fa 15 22 315 2.2 166 (0.5) Br/RF/Ob/SO/MR AB/NESP/AS/XL 9 88 11 13
18 M 19 21 468 1.9 178 (0.3) Br/RF/Ob AB/NESP/AS/XL 8 92 9 12
19 F 13 13 135 1.7 138 (2.8) Br*/SS/RF/Ob/MR AB/NESP/AS/XL 15 91 5 9
20 F 18 20 360 7.8 165 (0.1) Br/MR AB/NESP/AS/XL 12 83 18 11
21 M 6 7 80 7.5 107 (1.9) Br/SS/RF/Ob AB/NESP/AS/XL 3 98 5 6
22 F 5 6 107 9.2 102 (1.7) Br*/SS/RF/Ob/SO/MR AB/NESP/AS/XL 9 91 6 15
23 F 14 14 182 2.1 143 (3.5) Br/SS/RF/Ob/SO/MR AB/NESP/AS/XL 13 89 12 8
24 F 7 10 307 2.0 121 (2.0) Br/SS/RF/Ob AB/NESP/AS/XL 8 92 10 7
25 F 13 15 90 15.3 146 (2.3) Br/SS/RF/Ob/MR No 48 42 44 47
26 F 2 8 198 5.8 124 (0.7) Br/RF/SO No 38 45 34 47
27 F 12 13 109 5.1 140 (2.2) Br/SS/RF/Ob/SO No 47 40 42 39
28 M 5 5 130 7.5 113 (1.3) Br/RF/Ob/SO/MR No 41 39 45 42
29 F 1 12 281 10.4 150 (0.6) Br/RF/Ob/SO No 40 45 45 41
30 F 13 13 73 8.8 139 (2.6) Br*/SS/RF/Ob/SO No 43 38 35 40
31 F 11 22 452 13.2 168 (0.3) RF/MR No 45 42 44 37
32 F 15 15 105 50/88b 161 (0.1) Br/RF No 44 40 48 42
33 F 30 30 222 18.1 144 (2.8) Br*/SS/RF/Ob/SO/MR No 43 42 40 44
34 F 10 13 256 6.0 143 (2.1) Br/SS/RF/Ob/SO No 39 42 45 37
35 F 1 10 302 1.7 133 (0.2) Br/RF/SO No 46 41 36 40
36 F 12 12 95 4.8 152 (0.6) Br/RF/SO No 42 45 39 43
37 Fa 12 30 375 2.5 170 (1.5) Br/RF No 40 43 44 41
38 F 23 25 95 4.6 168 (0.5) Br/RF No 46 47 45 48
39 M 10 12 111 2.0 134 (2.0) Br/SS/RF/Ob/MR No 39 41 41 44
40 M 22 22 164 5.8 158 (3.0) Br/SS/MR No 37 42 38 40
F, Female; M, male; Br, brachydactyly, clinically evident; Br*, radiological evidence of brachydactyly; SS, short stature; RF, round face; Ob,
obesity defined as body mass index above 30 kg/m2 in adults or weight above the 97th centile in children; SO, sc ossifications. Age 1 refers
to the age (in years) at diagnosis; age 2 is the age at which short stature became apparent (during late infancy or puberty in most nonadult
patients) or, in those cases where short stature was absent, age 2 refers to the age at last evaluation and is italicized. PTH and TSH refer to
the levels at the time hormone resistance was discovered; normal values are 10–65 pg/ml for PTH, and 0.2–4.0 mIU/liter for TSH. Subclinical
hypothyroidism, i.e. elevated TSH levels with normal free thyroid hormones, is characterized by TSH levels between 4.2 and 10 mIU/liter. Height is
expressed in centimeters and always refers to age 2; target height SDS is reported in parentheses. The last column (% methylation) shows the
mean of three different determinations at each GNAS DMR. The degree of methylation is expressed as percentage of methylated cytosines divided
by the sum of methylated and unmethylated cytosines.
a Female patients with a history of nonspecific menstrual irregularities because of which combined oral contraceptive pill was started.
b For patient 32, instead of TSH, the FSH and LH levels (IU/liter) are shown, respectively.
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niques, as previously described (10, 11). Briefly, long-range PCR
was performed using Platinum Taq DNA Polymerase High
Fidelity (Invitrogen S.R.L.) at the manufacturer’s conditions
and two different couples of primers located at the boundaries
of each deletion and a smaller fragment in case of the presence
of a deleted STX16 allele. For multiplex PCR, we simulta-
neously used two pairs of primers giving raise to PCRproducts
of different length depending on the presence of the deleted
allele (Fig. 1B).
mRNA quantitative PCR analysis
Total RNA was isolated from peripheral blood cells using a
commercial kit (QIAGEN Rneasy mini kit; QIAGEN, Hilden,
Germany) according to the manufacturer’s instructions. After
digestionof genomicDNA,1gofRNAwas reverse-transcribed
through the Archive cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA). For Gs mRNA relative quanti-
fication, as well as for three housekeeping genes (18S, TBP, and
UBC), 10 ng of cDNAwas then amplified (TaqMan technology)
in a final PCR volume of 10 l using a 7900HT instrument (26,
27). Specific primers and probes for Gs mRNA are as follows:
forward primer, 5-GCTGCCTCGGGAACAGTAAG-3; reverse
primer, 5-GCTGCTTCTCGATCTTTTTGTTG-3; TaqMan
probe, 5-6-FAM-CCGAGGACCAGCGCAACGAGG-TAMRA.
Commercial gene expression assays (Applied Biosystems)
were used to amplify housekeeping genes, and assays num-
bers are: 18S, Hs9999901_s1; TBP, Hs00427620_m1;and
UBC, Hs00824723_m1.
All quantitative PCRs were carried out in duplicate and con-
firmed by two independent experiments. The geometrical mean
of the three reference genes was used as normalization factor for
Gs mRNA relative quantification (RQ) in 19 patients and in
seven normal subjects (used as controls). Gs was considered
differentially expressed if its RQ in a patient was at least de-
creased of 2.5-fold comparedwithGs averaged level quantified
in controls.
Results
Patients
The study included 40 patients (28 females and 12
males), all born from healthy, nonconsanguineous Cau-
casian parents. In all of them, a likely clinical diagnosis of
PHP-Ia was based upon the presence of PTH resistance
(i.e. hypocalcemia, hyperphosphatemia, and raised serum
PTHlevels in the absenceof vitaminDdeficiency) together
with at least two of the six AHO manifestations: brachy-
dactyly [shortening of fourth and/or fifth metacarpals de-
fined as the metacarpal sign and/or shortening below 2
SD score (SDS) at the metacarpophalangeal profile pattern
in at least one metacarpal bone or distal phalanx (Fig. 2)]
(19, 28), short stature (height below the third percentile
for chronological age), obesity (body mass index  30
kg/m2 in adults and97th centile in children), round face,
sc ossifications (either clinically evident or at x-ray), and
MR. In particular, in most patients, shortening of the
fourth and/or fifthmetacarpals was clinically evident, and
this was particularly true in all those patients in which
brachydactylywas themain clinical sign ofAHO(patients
1, 12, 15, 32, 37, 38) (Fig. 2). Mental retardation was
defined in case of a history of delayedmotor and/or speech
milestones or need of extra help in preschool or main-
stream school. The age at which the diagnosis was made
ranged between 1 and 30 yr. The majority of patients
showed either subclinical (n  21) or clinical (n  10)
hypothyroidism due to resistance to TSH. This was doc-
umented by raised serum TSH levels, in the absence of
antithyroid antibodies and in the presence of a normal
thyroid scan (data not shown). There was no evidence of
other endocrine defects in all the other patients but one, in
which resistance to gonadotropins was also present (pa-
tient 32), documented by elevated LH and FSH levels,
together with low estradiol levels and secondary amenor-
rhea. In the remaining patients, the onset of puberty was
regular, and sowas themenstrual cycle in females,with the
exception of patients 17 and 37, who developed oligo-
menorrhea. Nevertheless, we point out that at least 14
patients were still pre- or peripubertal at the time of last
evaluation, and menstrual irregularities may become ap-
parent during the next few years. Gonadotropin, ACTH,
and cortisol levels, aswell as estradiol levels in females and
testosterone levels inmales,were in thenormal range (data
not shown). Clinical and biochemical details are shown in
Table 1. Informed consent was obtained from all subjects
involved in the study.
Molecular analysis
Sequencing analysis confirmed the absence of muta-
tions inGs-codingGNAS exons.All patientsdisplayedat
least one of the known polymorphisms present in Gs-
FIG. 2. Left hand x-rays of cases 1 (A) and 7 (B). Although the
metacarpal sign is evident in patient 1 (who showed clinically evident
brachymetacarpia), patient 7 exhibited shortening of all metacarpal
bones and of I, IV, and V distal phalanx according to z-score
calculations 2 SDS in comparison with normal subjects.
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coding sequence (C/T at positions 749, 911, and 1469 in
exons 5, 7, and 11, respectively; NM000516), excluding
the existenceof largedeletions comprising the gene.More-
over, to rule out deletions in the upstream region of
GNAS, we analyzed a known polymorphic pentanucle-
otide repeat within the A/B DMR, as well as six single
nucleotide polymorphisms (SNPs) within the NESP55 re-
gionandeight SNPs in theXL-A/B intronic region: overall,
each patient was heterozygous for at least one of these
SNPs in each region, and looking at the polymorphic
pentanucleotide repeat as well as at each SNP individually,
we found percentages of heterozygosity similar to those
reported in the literature (SupplementaryTable 2) (19, 23,
24).Moreover, in those patientswhose parents’ DNAwas
available, we found concordant SNP patterns (data not
shown).Taken together, these resultsmake thepresenceof
deletions in these regions highly unlikely.
Of the 40 patients included in the study, 24 showed
methylation defects at GNAS DMRs, thus indicating
PHP-Ib as the correct diagnosis at themolecular level (Ta-
ble 1 and Fig. 1C). In particular, all patients showed loss
of methylation at exon A/B, a condition today commonly
thought to be sufficient to determine PHPmanifestations.
According to the apparent sporadic form of the disease in
our patients, in addition to methylation defects at exon
A/B, all hadmultiple additional methylation changes (loss
of methylation at XL and AS DMRs and gain of methyl-
ation at NESP DMR). Moreover, none of them showed
STX16 deletions as assessed by long-range and multiplex
PCRs (Fig. 1D). Finally, parents’ DNA from eight patients
was available, and the analysis ofGNASmethylation pat-
tern gave normal results (patients 5, 6, 9, 13, 14, 19, 23,
24; data not shown).
Quantification of the Gs transcript by real time RT-
PCR in 19 of our 40 patients (12withmethylation defects,
seven with normal methylation pattern) revealed a reduc-
tion of gene expression compared with controls (seven
normal subjects, averagedRQ6.91.34) in 10 of them
(patients 2, 7, 8, 14, 15, 16, 18, 22, 31, 33; averagedRQ
1.38 1.11), whereas an expression similar to the one in
normal subjects was observed in nine patients (patients 3,
10, 12, 23, 29, 34, 37, 39, 40; averaged RQ  5.24 
1.73). These results were found regardless of the methyl-
ation status or clinical manifestations.
Similarly, no correlation was observed in our study be-
tween the presence or absence of methylation defects and
the severityofAHO. In fact, as shown inTable1,our series
included patients who displayed the typical AHO features
with either broadmethylation alterations (patients 2–6, 8,
9, 16, 17, 19, 22, 23) or normal methylation pattern (pa-
tients 25, 27, 28, 30, 33, 34, 39), as well as vice versa,
patients with only two signs of AHO and either a normal
pattern (patients 31, 32, 37, 38) or an abnormal pattern
(patients 1, 10, 12, 15, 20) of methylation. Finally, there
was no correlation between the methylation pattern and
the number or severity of hormonal resistances.
Discussion
Here we report a screening study for methylation defects
at the GNAS locus in patients with AHO features and
hormonal resistance but absence ofmutations inGs-cod-
ing exons. This study,which represents the largest series in
the literature with complete clinic and genetic/epigenetic
assessment, included40patientswhodisplayed the typical
features of PHP-Ia, i.e. multihormonal resistance in the
presence of AHO. In these patients, molecular analysis
excluded the genetic defects inGNAS coding exons (1–13)
usually associated with PHP-Ia, i.e. loss of function mu-
tations, large deletions, and paternal unidisomy. More-
over, the observation that all patients were heterozygous
for at least one polymorphism in each A/B, NESP55, and
XL-A/B intronic regionmakes the presence of deletions in
these regions highly unlikely.
Molecular analysis demonstratedmultiplemethylation
defects at the GNAS locus in the absence of STX16 mi-
crodeletions in60%ofourpatients.This allowedus, at the
molecular level, to reclassify those individuals as having
sporadic PHP-Ib. Three recent independent reports re-
vealed similar molecular patterns in seven patients previ-
ously diagnosed with PHP-Ia and subsequently found to
have PHP-Ib (19–21). Six of these patients displayedmild
AHO, as suggested by rounded face and slight metacarpal
shortening (19, 21). Conversely, in our study no correla-
tion between the presence or absence of methylation de-
fects and the severity of AHO was observed.
ThepresenceandextentofAHOfeatures in thepatients
included in the present series are key points, many of the
individual features of AHO being nonspecific to PHP (1).
A classical hallmark of PHP-Ia, i.e. sc ossifications, was
present in 19 patients, regardless of the methylation de-
fects.As for thebonephenotype, althoughwe followed the
most commonly used and accepted radiological criteria
for establishing the presence of brachydactyly, in the large
majority of our patients this sign was clearly clinically
evident, with no real necessity of radiological measure-
ments. As forMR, there are no standardized tests defining
it in PHP, and the frequency and severity of this sign are
not well established. As in most reported series, we have
defined a patient as having MR in case of a history of
delayed motor and/or speech milestones or need of extra
help in preschool or mainstream school. In general, ac-
cordingly with the literature, all of our patients with MR
could be classified as having mild/moderate MR, and the
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prevalence of MR was similar to that observed in other
large reports (47.5% in our series; 65% reported in Refs.
29 and30). Finally, nonspecific signs such as short stature,
rounded face, and obesity were also frequently present in
our series, as commonly reported in PHP-Ia. Overall, the
large number of patients included in the present study as
well as the association of different specific and nonspecific
AHO-like features in each individual should exclude the
possibility that the phenotype of these patients might be
unrelated to GNAS-imprinting defects. The absence of
the same features in relatives further strengthens the
association between clinical characteristics and molec-
ular findings.
As reported in both PHP-Ia andPHP-Ib, themajority of
patients showed either subclinical or clinical hypothyroid-
ism due to resistance to TSH. There was no evidence of
other endocrine defects, although it was difficult to draw
definite conclusions on gonadotropin resistance in the
present series, due to the good proportion of prepubertal
females or females just coming throughpuberty at the time
of evaluation. Unfortunately, most of our patients with
short staturewere not tested forGHdeficiency, andweare
therefore unable to give additional information on this
issue at this moment.
In accordance with the report by de Nanclares et al.
(19), our data further strengthen the hypothesis that Gs
expression in humans is subject to individual-specific al-
lelic imprinting in a number of tissues larger than that
classically thought, i.e. the renal proximal tubule and the
thyroid. Individual-related variance in Gs expression in
bone (chondrocytes and osteoblasts), central nervous sys-
tem, and adipose tissue may account for the presence or
absence of specific AHO manifestations (31, 32). In par-
ticular, as far as bone is concerned, althoughGs has been
found to be biallelically expressed in this tissue, we dem-
onstrated a modest maternal predominance of its tran-
script in one of the human bone samples investigated, fur-
ther supporting the variability in the degree of allelic bias
in selected tissues (31). Recent studies in mice show that
Gs paternal imprinting in the central nervous system
leads to a specific defect in the ability of central melano-
cortins to stimulate sympathetic nervous system activity
and energy expenditure, and this could account for obesity
in PHP-Ia patients (32). In turn, the variable contribution
of the paternal allele in Gs expression in the thyroid
would be responsible for the existence of the broad spec-
trum of thyroid function alterations observed in these pa-
tients, ranging from normal function to neonatal overt
hypothyroidism (17, 18).
In conclusion, we report a large molecular analysis of
patients with clinical PHP-Ia and absence of mutations in
Gs-coding exons. Molecular evaluation showed that
more than 50% of such patients could be classified as
sporadic PHP-Ib at the molecular level. It is becoming
evident that PHP-Ia and PHP-Ib share more genetic and
clinical similarities than previously thought because both
diseases end up with silencing or reduction of Gs tran-
scription in selected tissues. The presence of TSH resis-
tance both in PHP-Ib and PHP-Ia patients firstly sup-
ported this hypothesis (9, 10). The incoming data showing
that the twodiseases also share commonepigenetic defects
further strengthen this lineof evidence and, inouropinion,
highlight theneed for anewclassificationof thesediseases.
Finally, we propose that bothmutational analysis of Gs-
coding GNAS exons and evaluation of epigenetic defects
should be considered in patients with PTH resistance and
AHO-like features, regardless of their severity.
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